Xeris Biopharma Holdings, Inc. $XERS Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 78.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 161,793 shares of the company’s stock after buying an additional 71,148 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Xeris Biopharma were worth $938,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after buying an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares during the period. Finally, Truvestments Capital LLC boosted its holdings in Xeris Biopharma by 96.1% in the fourth quarter. Truvestments Capital LLC now owns 8,118 shares of the company’s stock valued at $64,000 after acquiring an additional 3,979 shares during the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Xeris Biopharma

In related news, insider Steven Pieper sold 27,600 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total value of $235,152.00. Following the completion of the sale, the insider directly owned 1,366,053 shares of the company’s stock, valued at $11,638,771.56. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the sale, the director owned 126,500 shares in the company, valued at $770,385. The trade was a 11.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 251,500 shares of company stock valued at $1,846,457. Corporate insiders own 4.35% of the company’s stock.

Xeris Biopharma Stock Performance

XERS opened at $8.34 on Monday. The stock has a market capitalization of $1.44 billion, a PE ratio of 139.00 and a beta of 0.62. The firm’s fifty day moving average price is $6.86 and its 200 day moving average price is $6.68. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.87 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.